Latest Biotech News

A phase Ib study in newly diagnosed glioblastoma reported results for a personalized neoantigen-pulsed, autologous dendritic cell vaccine approach, published in Nature Communications. The regimen...

Researchers reported small-molecule-controlled CRISPR genome editing systems that keep nuclease activity largely off until drug induction. In a Science Translational Medicine paper, a team led by...

United Therapeutics agreed to pay $140 million upfront to acquire Thymmune Therapeutics, a preclinical-stage regenerative cell therapy company focused on restoring thymic function. The deal...

AstraZeneca entered a new kidney-focused discovery collaboration with CSPC Pharmaceutical, agreeing to pay $30 million upfront and jointly develop two kidney disease drug candidates. The pact is...

Ipsen agreed to acquire Memo Therapeutics AG in a deal valued at up to €700 million ($800 million), adding a first-in-class monoclonal antibody candidate targeting BK polyomavirus associated...

Brightpath Biotherapeutics filed an IND with the FDA to initiate a Phase I U.S. clinical trial of BP-2202 for multiple myeloma. The company’s submission is set to begin testing under...

Countable Labs introduced a single-molecule precision PCR platform designed to directly count nucleic acids rather than rely on statistical inference. In an Innovation Spotlight, CEO Giovanna...

Arvinas highlighted its clinical-stage PROTAC platform progress in an interview-style feature, framing PROTAC as the first widely cited example of the modality reaching the market pipeline and...

Scribe Therapeutics filed for a Nasdaq IPO, targeting investor interest in early-stage gene-editing and CRISPR-enzyme development. The filing marks a pivotal fund-raising step for the company,...

The newsletter includes a listing related to the Swedish Pavilion at BIO International 2026, including co-organizers and partners. The item appears to be event-directory content rather than a...

United Therapeutics agreed to buy Thymmune Therapeutics in a $140 million upfront deal, with up to $160 million in milestones tied to clinical and regulatory progress through 2031. Thymmune’s...

Roche said new phase 3 data for divarasib support a potency and selectivity advantage versus first-generation KRAS G12C inhibitors, including competitor regimens from Amgen and Bristol Myers...

Researchers led by Wang Yu at the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences reported dual small-molecule-controlled CRISPR editing systems, PRINCE and Little...

Insilico Medicine and Takeda expanded a drug-discovery collaboration built around AI-driven candidate selection. Insilico will use its platform to identify molecules meeting predefined scientific...

Brightpath Biotherapeutics submitted an IND application to the FDA to begin a phase I U.S. trial of BP-2202 for multiple myeloma. The filing is tied to NCT07667868 and marks the next step in...

Merck Sharp & Dohme disclosed new benzimidazole derivatives that act as NLRP3 inflammasome inhibitors through a patent filing. The company framed potential use across indications spanning...

ATB Therapeutics presented its antibody-peptide fusion platform, dubbed “atbodies,” aimed at improving the therapeutic window versus conventional antibody-drug conjugates. Speaking at the Antibody...

USC researchers reported synthetic organizers that improve reproducibility in human kidney organoid formation by engineering Wnt-secreting cells based on developmental mapping. In a Science paper,...

Countable Labs introduced a single-molecule PCR counting approach designed to improve sensitivity and run-to-run reproducibility versus statistical-inference methods. The company’s platform...

AstraZeneca returned to CSPC Pharmaceutical with a new kidney disease drug discovery collaboration worth up to $1.7 billion, following a prior package with the Chinese partner earlier this year....